XBI
SPDR S&P Biotech ETFPrevious close
151.40
Change
−1.54%
Expense ratio
0.35%
AUM
$10.4B
Holdings
165
14% look-through
YTD
+24.2%
1Y
+44.2%
5Y
+21.0%
Returns
Price return, excluding dividends| 1M | 3M | YTD | 1Y | 3Y | 5Y | |
|---|---|---|---|---|---|---|
| XBI | −3.1% | −2.5% | +24.2% | +44.2% | +117.5% | +21.0% |
| SPY | +1.8% | +3.9% | +14.1% | +19.2% | +80.3% | +74.5% |
| Difference | −4.9% | −6.4% | +10.1% | +25.1% | +37.2% | −53.5% |
| Ticker | Company | Weight |
|---|---|---|
| MRNA | Moderna | 2.35% |
| — | TWIST BIOSCIENCE CORPNot covered | 1.87% |
| — | NATERA INCNot covered | 1.78% |
| ABBV | AbbVie | 1.67% |
| — | IOVANCE BIOTHERAPEUTICS INCNot covered | 1.64% |
| BIIB | Biogen | 1.63% |
| AMGN | Amgen | 1.59% |
| — | UNITED THERAPEUTICS CORPNot covered | 1.59% |
| GILD | Gilead Sciences | 1.54% |
| — | HALOZYME THERAPEUTICS INCNot covered | 1.51% |
| — | EXELIXIS INCNot covered | 1.51% |
| — | TG THERAPEUTICS INCNot covered | 1.49% |
| VRTX | Vertex Pharmaceuticals | 1.45% |
| — | PROTAGONIST THERAPEUTICS INCNot covered | 1.45% |
| — | SPYRE THERAPEUTICS INCNot covered | 1.45% |
| — | CRISPR THERAPEUTICS AGNot covered | 1.44% |
| — | VAXCYTE INCNot covered | 1.41% |
| REGN | Regeneron Pharmaceuticals | 1.41% |
| — | PTC THERAPEUTICS INCNot covered | 1.41% |
| — | KRYSTAL BIOTECH INCNot covered | 1.40% |
| — | GRAIL INCNot covered | 1.37% |
| — | NEUROCRINE BIOSCIENCES INCNot covered | 1.35% |
| — | REVOLUTION MEDICINES INCNot covered | 1.34% |
| — | ERASCA INCNot covered | 1.34% |
| INCY | Incyte | 1.32% |
Look-through checkup
Valuation, growth and FinDog views of the holdings, weighted by position; covers 14% of the fund5-year valuation percentile
50
Where each company's P/E sits in its own 5-year range, weighted
Revenue growth (YoY)
+14.9%
Position-weighted
Gross margin
70.9%
Position-weighted
Holdings dividend yield
1.36%
Position-weighted
Reported
13%
91% of look-through weight
EPS beat
76%
of reported weight
EPS miss
24%
of reported weight
Guidance raised
0.0%
Guidance cut
0.0%
Top holdings that have reported